Get more generic medication on the market.

Glenn Grothman · Wisconsin · Republican

policy impact 0.50 specificity 0.60 extraction confidence 90%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

Get more generic medication on the market.

Commits to increasing the availability of generic medications.

Home - Glenn Grothman
campaign · campaign_site · model gpt-5.4-mini

Evidence

legacy_unverified · Source version not recorded · locator unknown

Grothman's campaign site lists "Get more generic medication on the market" among priorities for Wisconsin's Sixth Congressional District.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The commitment is still presented as a campaign priority, but the page does not claim completion or identify a delivered policy result.

unresolved unknown

Home - Glenn Grothman
campaign · model gpt-5.5 · confidence 89%

legacy_unverified · Source version not recorded · locator unknown

FDA says first generic approvals permit a manufacturer to market a generic product in the United States and lists 2026 first-time generic approvals; it also cautions approved drugs are not always available immediately.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Within the lookback window, FDA's current page shows generic approvals continue under federal processes, but it does not tie those approvals to Grothman and approval alone does not prove market availability.

partial unknown

First Generic Drug Approvals | FDA
secondary · model gpt-5.5 · confidence 78%

legacy_unverified · Source version not recorded · locator unknown

Congress.gov records Grothman as sponsor of H.R.8190. The bill would deem FDA-approved biosimilar insulin interchangeable with the reference product; its status remained Introduced, with latest action on September 16, 2020.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Grothman took concrete legislative action to expand biosimilar insulin, a biologic analogue to generic competition, but the bill did not become law.

partial unknown A for effort

H.R.8190 - Biosimilar Insulin Access Act of 2020
secondary · model gpt-5.5 · confidence 91%

legacy_unverified · Source version not recorded · locator unknown

Grothman's office said the Biosimilar Insulin Access Act would waive interchangeability requirements for biosimilar insulin and make lower-cost insulin options more widely available to patients.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The statement confirms the purpose of Grothman's bill was to increase competition and availability of biosimilar insulin, but it describes a proposal rather than an enacted result.

partial unknown A for effort

Grothman Introduces Bill to Increase Insulin Competition and Affordability
secondary · model gpt-5.5 · confidence 90%

legacy_unverified · Source version not recorded · locator unknown

Congress.gov lists Grothman as a cosponsor of H.R.2212 on September 28, 2018. The bill's official title sought to promote competition by facilitating timely entry of lower-cost generic and biosimilar versions of drugs.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Grothman supported a bill directly aimed at generic and biosimilar market entry, but this 115th Congress version did not advance beyond introduction/referral.

partial unknown A for effort

H.R.2212 - CREATES Act of 2017
secondary · model gpt-5.5 · confidence 92%

legacy_unverified · Source version not recorded · locator unknown

Congress.gov says H.R.965 aimed to facilitate timely entry of lower-cost generic and biosimilar products and identifies related H.R.1865 as becoming Public Law 116-94 on December 20, 2019.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): A federal generic-competition policy related to the CREATES Act was enacted during Grothman's House service, but this source does not show Grothman sponsoring the enacted version.

partial unknown

H.R.965 - CREATES Act of 2019
secondary · model gpt-5.5 · confidence 82%

legacy_unverified · Source version not recorded · locator unknown

Congress.gov lists Grothman as an original cosponsor of H.R.19. The bill summary says it would revise regulatory approval and commercial availability provisions for generics and biosimilars; the bill remained introduced.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Grothman backed a broader drug-pricing package with generic and biosimilar provisions, but it was not enacted.

partial unknown A for effort

Cosponsors - H.R.19 - Lower Costs, More Cures Act of 2019
secondary · model gpt-5.5 · confidence 87%

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): never. unknown A for effort

Grothman repeatedly advanced related drug-competition legislation, including sponsorship and cosponsorship of bills aimed at speeding generic and biosimilar entry, but the cited measures did not become law and the record does not show that his promise was actually achieved. The campaign priority remained an aspiration rather than a completed outcome.

provider codex_cli · model gpt-5.4-mini · confidence 91%